"Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money."
#Immunology #immunotherapy #CheckpointInhibitor

https://www.fiercebiotech.com/biotech/novartis-calls-time-tim-3-axing-cancer-candidate-after-phase-3-flop